BIOC Stock - BioClinica Inc.

BIOC Stock Chart

BIOC Profile

Biocept, Inc. is a pioneering molecular oncology diagnostics company that specializes in developing and commercializing proprietary assays for circulating tumor cells (CTCs) and circulating cell-free tumor DNA and RNA. These assays utilize standard blood samples to provide crucial information to healthcare providers. By identifying oncogenic alterations, Biocept's cancer assays help guide targeted therapy decisions at various stages of cancer management, including diagnosis, progression monitoring, and identifying resistance mechanisms. The company's portfolio includes assays for a range of solid tumor indications such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.

In addition to its diagnostic services, Biocept offers cerebrospinal fluid tumor cell testing, ctDNA and ctRNA testing, and RT-PCR testing services for COVID-19. These services cater to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other healthcare professionals. Biocept also provides clinical trial and research services to pharmaceutical companies, biopharmaceutical companies, and clinical research organizations, leveraging its expertise in molecular assays.

Founded in 1997 and headquartered in San Diego, California, Biocept continues to innovate through collaborations and partnerships. It has collaborated with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and results. Additionally, Biocept collaborates with Protean BioDiagnostics, Inc. to research the use of its Target Selector molecular assay in determining EGFR status in NSCLC patients. These collaborations underscore Biocept's commitment to advancing precision medicine and improving patient outcomes through cutting-edge molecular diagnostics.

BIOC Revenue Chart

BIOC Earnings

Analyst Ratings